Breast Cancer Clinical Trial
Official title:
Case Control Study to Evaluate the Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction
The investigators intend to undertake a study to investigate the effect of radiotherapy on
deep inferior epigastric perforator flap reconstructions (DIEP). Adjuvant post-mastectomy
radiotherapy (PMRT) is offered to women at high risk of chest wall recurrence. The perceived
detrimental effect of radiotherapy on an immediate breast reconstruction and the "one-off"
nature of autologous reconstruction leads some surgeons to recommend delayed reconstruction
after mastectomy or to use a temporising implant with a view to planned exchange to
autologous reconstruction after radiotherapy. However, there remains significant uncertainty
in the literature about the impact of radiotherapy on autologous reconstructions. This study
is a mixed methology study using patient reported outcome measures (PROMS), applanation
tonometry (measure of breast compressibility), semi-structured interviews and 3 dimensional
photography analysis to compare the aesthetic and impact on quality of life on the following
groups of patients:
Patient groups:
1. Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and
PMRT (cases)
2. Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
3. Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction
(controls)
4. Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP
(controls)
Since 1997, breast cancer has been the most common cancer in the UK, accounting for 31% of
all new cancers in women. According to the latest statistics published by Cancer Research
UK, approximately 50,000 women were diagnosed with breast cancer in 2010(1). In the UK, 53%
of women with symptomatic breast cancer and 27% of those with screen-detected breast cancer
are treated surgically with mastectomy; therefore approximately 21,500 undergo a therapeutic
mastectomy each year (2). Guidelines from the National Institute for Health and Clinical
Excellence (NICE) recommend that immediate breast reconstruction is offered to women during
the same operation as their mastectomy (3). The UK National Mastectomy and Breast
Reconstruction Audit Second Report 2009 (4) states that 21% of their cohort underwent
immediate breast reconstruction, thus one would expect approximately 4500 women to undergo
immediate reconstruction each year in the UK.
A breast reconstruction should mimic the natural appearance of the breast in shape, volume
and compliance, together giving a symmetrical result. Breast reconstruction ranges from
implant-based methods to autologous free flap reconstruction, such as the deep inferior
epigastric perforator (DIEP) flap, which was first popularised by Allen in 1994(5). In our
unit, the DIEP flap has become one of the most reliable and popular methods of breast
reconstruction, with flap failure rate of less than 1%. We, like others, view it as the
current "gold standard" in breast reconstruction(6)(7)(8).
Adjuvant post-mastectomy radiotherapy (PMRT) is offered to women at high risk of chest wall
recurrence. The perceived detrimental effect of radiotherapy on an immediate breast
reconstruction and the "one-off" nature of autologous reconstruction leads some surgeons to
recommend delayed reconstruction after mastectomy or to use a temporising implant with a
view to planned exchange to autologous reconstruction after radiotherapy. However, there
remains significant uncertainty in the literature about the impact of radiotherapy on
autologous reconstructions . Initially, small case series supported the clinical bias that
radiotherapy is detrimental to the autologous reconstruction but, more recently, larger
series have challenged this view. Each study has flaws, such as being underpowered, having
insufficient duration of follow up, not reporting patient satisfaction or not measuring
volume objectively such that residual questions remain. A recent systematic review by Kelley
et al attempted to address questions related to complications and flap compromise as a
result of radiation delivery before or after autologous breast reconstruction. The review
analysed 20 articles with over 1,500 flap reconstructions. No significant differences in
measurable postoperative complications including total flap loss, wound healing
complications, infection, haematoma, seroma, and fat necrosis were found in comparing
patients who underwent PMRT before or after autologous reconstruction. However, differences
in cosmetic outcome and patient satisfaction in the irradiated and unirradiated flap
reconstruction groups were not adequately addressed.
The heterogeneity of opinion in the literature on the impact of radiotherapy makes patient
information and decision-making difficult. It may be that the detrimental effect of
radiotherapy is outweighed in terms of patient satisfaction by the benefit of immediate
reconstruction with a definitive reconstruction and that surgeons' concerns are overvalued,
yet it is upon this anecdotal surgeon-reported outcome that patient decision making is
based.
In an era when breast cancer patients are more likely to survive their disease (85% for 5
year survival), the physical and psychological effects of treatment, especially long term
effects, are very relevant. A woman with residual dissatisfaction with her reconstructed
breast has a constant reminder of her disease and treatment. Optimising reconstructive
outcomes is a major issue in survivorship.
Rationale
Surgeons strive to attain the best possible reconstructive outcomes and are aware of the
effects of radiotherapy on an autologous flap. They therefore often advise against any
procedure which may have a detrimental impact on "their" flap. However, from a patient
perspective, by having a delayed reconstruction the treatment pathway is prolonged by
several months, if not years, and requires an additional operation(s) compared to those who
undergo immediate reconstruction and PMRT. There remains significant uncertainty in the
literature about the magnitude of the impact of radiotherapy from a surgeon's perspective
and very little is known about the patients' preferences in terms of detrimental impact on
flap vs effect of the prolonged pathway on their lives.
By objectively assessing irradiated autologous flap reconstructions and comparing with
unirradiated patients we will understand further the impact of radiotherapy on an autologous
flap. By quantifying the difference in patient satisfaction, and understanding the
perspective of patients who have PMRT to an immediate or delayed reconstruction we will
understand further the impact of both pathways on their lives, the reconstruction and their
satisfaction with the result. This, we believe, will enable clinicians to better inform
patients, empowering them in their decision-making about the best timing for breast
reconstruction and potentially enabling more women to undergo immediate definitive breast
reconstruction with DIEP flap.
We intend to enrol patients who have undergone unilateral mastectomy and DIEP
reconstruction. Patients will fall into one of four possible groups depending on the
decision made by the surgeon and patient pre-operatively.
Patient groups:
1. Unilateral skin sparing mastectomy (SSM) with immediate DIEP flap reconstruction and
PMRT (cases)
2. Unilateral SSM with immediate DIEP flap reconstruction and no PMRT (controls)
3. Unilateral simple mastectomy, PMRT, and subsequent delayed DIEP flap reconstruction
(controls)
4. Unilateral SSM with temporizing implant, PMRT and subsequent conversion to DIEP
(controls)
The study will be conducted as a mixed methods case control study using both quantitative
and qualitative research methods. Initially a prospective study was planned, however for
those patients who undergo a delayed reconstruction the whole oncological and reconstructive
process can take several years. Secondly the number of patients who are currently undergoing
radiotherapy to their DIEP breast reconstruction is relatively small. For these reasons it
was decided that a truly prospective study would not be practical but prospective data
collection from a recent cohort of patients would yield a greater study population.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |